Skip to main content
$3.35 -$0.09 (-2.6%)

04:00 PM EST on 02/21/24

Aldexa Therapeutics (NASDAQ:ALDX)

CAPS Rating: No stars

Current Price $3.35 Mkt Cap $197.1M
Open $3.42 P/E Ratio -4.31
Prev. Close $3.35 Div. (Yield) $0.00 (0.0%)
Daily Range $3.28 - $3.47 Volume 87
52-Wk Range $1.42 - $11.97 Avg. Daily Vol. 1,002,299


How do you think NASDAQ:ALDX will perform against the market?

Add Stock to CAPS Watchlist

All Players

16 Outperform
3 Underperform

All-Star Players

2 Outperform
3 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:ALDX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (98.78)
Submitted May 26, 2015

At first glance, Aldeyra is a very uninspiring stock. The company raised only 11M from a below range IPO at 8 a year ago, and the share price has remained weak since then. A breakout to 12 in January eventually lead to a steep decline which is… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!


Recent Community Commentary

Read the most recent pitches from players about ALDX.


Member Avatar mfred (< 20) Submitted: 9/21/2017 11:51:35 AM : Outperform Start Price: $8.38 NASDAQ:ALDX Score: -159.12

The chances of ALDX delivering a stong drug to the market to treat drye eye disease looks quite good as it the mid stage clinical trials for ADX-102 look very good.


Member Avatar zzlangerhans (98.78) Submitted: 5/26/2015 12:16:51 PM : Outperform Start Price: $7.07 NASDAQ:ALDX Score: -187.87

At first glance, Aldeyra is a very uninspiring stock. The company raised only 11M from a below range IPO at 8 a year ago, and the share price has remained weak since then. A breakout to 12 in January eventually lead to a steep decline which is continuing as I write, and the stock is now well below the IPO price. The IPO was underwritten by Aegis, a horrendous brokerage with a reputation for trading promotion for the banking business of weak biotechs and outright scams. The stock has attracted almost no analyst coverage and little institutional ownership. On the last conference call, one analyst from a third tier outfit had the floor to himself in the Q & A. Seeking Alpha and even the grotesque YMB have left the stock untouched.

Why had Aldeyra been such an object of disdain from the moment of inception as a public company? It's difficult for me to tell, due to the lack of commentary both positive and negative. The science is not obviously faulty. Aldeyra is developing NS2, a small molecule "trap" of aldehyde, which the company claims is a mediator of inflammation in numerous diseases such as autoimmune conditions, atherosclerosis, and diabetic nephropathy. That's an uh-oh. If they're going to claim such a broad spectrum of activity, they should back it up with a little science but the company website is exceptionally devoid of science. Are they just keeping their cards close to their chest? Perhaps, but first they need to come to the poker table.

I'm skeptical about the aldehyde hypothesis for inflammatory diseases but what captured my attention is that NS2 is being evaluated in a phase II trial for Sjogren-Larsson Syndrome (SLS), a rare genetic enzyme deficiency that results in accumulation of aldehyde. There is no effective treatment for the disease itself, but only palliative therapies for the complications. Could an aldehyde trap be a game changer for an incurable disease caused by accumulation of aldehyde? Doesn't seem too farfetched. Unfortunately, there's a dearth of information regarding anti-aldehyde therapy for SLS in the literature, or on Aldeyra's website. There's been a knockout mouse model of SLS since 2006. Has NS2 been tested on it? I don't know.

SLS is a rare disease whose worldwide prevalence is unknown, but may be as high as 1 in 200000. That's a total prevalence of about 10000 in what's known as the reimbursable world. Far from being a number to scoff at, it's comparable to the number of patients estimated to have CESD. That's the disease being addressed by Synageva, which is now valued at eight billion dollars after agreeing to be bought out by Alexion. Alexion's market cap is over thirty-three billion thanks to their treatment for the ultrarare disease PNH.

There's no question that if NS2 doesn't work for SLS, and no one really pays attention to the stock before they report failure in the trial, that Aldeyra will probably end up being worthless. On the other hand, IF anyone with some pull starts flogging this stock before phase II data OR the drug actually works, don't expect the market cap to stay under 50M.


Find the members with the highest scoring picks in ALDX.

Score Leader


whatsthepoint (99.84) Score: +127.56

The Score Leader is the player with the highest score across all their picks in ALDX.

Member Name Member
Call Time
Score Commentary
Under5 58.49 10/20/2023 Outperform 5Y $1.67 +100.60% +15.38% +85.22 0 Comment
CancelAccount99 99.78 5/15/2020 Underperform 5Y $3.65 -8.22% +76.06% +84.28 0 Comment
Toprope101 98.09 3/5/2020 Underperform 5Y $3.74 -10.43% +63.00% +73.43 0 Comment
whatsthepoint 99.84 3/26/2020 Underperform 5Y $2.00 +67.50% +93.32% +25.82 0 Comment
ababrmon 26.15 9/28/2021 Outperform 5Y $8.75 -61.71% +14.24% -75.96 0 Comment
karakartal < 20 12/19/2019 Outperform 5Y $5.09 -34.18% +55.35% -89.53 0 Comment
foggs1 47.61 4/29/2021 Outperform 5Y $12.98 -74.19% +18.29% -92.48 0 Comment
odocoileus < 20 10/26/2020 Outperform 5Y $7.30 -54.11% +47.23% -101.34 0 Comment
DrDGP < 20 10/15/2019 Outperform 3Y $5.32 -37.03% +66.24% -103.27 0 Comment
mjonesy1985 91.70 10/1/2018 Outperform 3W $13.38 -74.96% +69.89% -144.84 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ALDX.